Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — MRI Interventions — Investor Presentation (December 2019)
16 slides from Clearpoint Neuro's investor presentation, Dec 9, 2019
Slide 1: ClearPoint Investor Presentation
CLEARPOINT ” PRECISE NEURO NAVIGATION aT THERAPY Investor Presentation Joe Burnett, President & CEO December 2019 ee
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance
Slide 3: Only a fraction of patients with debilitating neurological disorders are being treated surgically today
Only a fraction of patients with debilitating neurological disorders are being treated surgically today Prevalence of Neurological Disorders 0 09 © © o © 9 9 © © @ © © 0 o0 ©» 0 ©0 0 © © © © © o0 © © © © © 0 © © @ © © @ © o @ © © 0 © © © 9 © © © © © © © © © © @ © © © 0 © © oo © o © © © © 9 © @ ©0 o0
Slide 4: The Movement to Minimally Invasive Procedures has Happened Everywhere Else in the Body
The Movement to Minimally Invasive Procedures has Happened Everywhere Else in the Body This transition has always had two things in common: ° More patients being treated ¢ Procedures enabled by live image guidance © 2019 MRI INTERVENTIONS, INC 4
Slide 5: Primary Challenge: Traditional Stereotactic Neurosurgery is Limited
PRIMARY CHALLENGE Traditional Stereotactic Neurosurgery is Limited The Skull is Not ‘See Through’ ¢ X-Ray and CT do not show structures of the brain ° Large, Metallic Navigation Frames are not compatible inside an MRI Magnet ¢ Surgical Image Guidance in the Operating Room is not live but rather ‘Co-
Slide 6: Our Solution: ClearPoint Neuro Navigation Platform
R LUTION OUR SOLUTIO MRI ClearPoint® Neuro Navigation = ~~ Platform An MRI Compatible Navigation System Delivering Live MRI Guidance during the Procedure © 2019 MRI INTERVENTIONS, INC | 6
Slide 7: Our Solution
OUR SOLUTION
Slide 8: Our Company: MRIC & ClearPoint: A Proven Platform
OUR COMPANY ws MRIC & ClearPoint: A Proven Platform ~ Key Products: FDA C€ Marked Platforms; More than 3,000 Procedures Performed to HEADQUARTERS. EMPLOYEES Irvine, CA 40+ 19 sales | 19 production & development 2018 REVENUE 2019 REVENUE FORECAST $7.4m $10.5m —11.5m" Razor / Razorblade model with 80%
Slide 9: Broad and Growing User Base of Leading Neurosurgeons
BROAD AND GROWING USER BASE OF LEADING NEUROSURGEONS ClearPoint” s Installed in 57 Active U.S. Clinical Sites and Growing UC San Francisco oo Texas Chil San Francisco VA Stanford Univ Lucile Packard (Stanford Children’s) UCSF Benioff Childrens UC San Diego Univ of Colo Univ of Utah Univ of Arizona C
Slide 10: Our MRI-Guided Therapy Platform is currently being used to...
Our MRI-Guided therapy platform is currently being used to... IMPLANT NEURO PLACE LASER DELIVER BIOLOGICS MRIC PLATFORM RUNS STIMULATION LEADS ABLATION PROBES AND DRUGS. ON ALL MAJOR SCANNERS. Medtronic Medtronic eyager ©Veyag SIEMENS VISUALASE THERAPEUTICS MONTERIS PTC MEDICAL / THERAPEUTICS AV. Bo
Slide 11: MRIC Capabilities
MRIC CAPABILITIES Our platform enables choice of precision-guided therapies and services Gene Field & Drug Product Clinical Delivery Development Services Services Deep Brain Stimulation Laser Ablation Tumor Biopsy CLEARPOINT Hardware & Software _—_ Artificial Intelligence Robotics Tumor Immuno- ther
Slide 12: Example: The Parkinson's Disease Patient
MRIC CAPABILITIES MRI Example: The Parkinson’s Disease Patient ™~ Enabling Surgeons to choose the right tool for the right patient Gene & Drug Delivery Laser Ablation Applicators © 2019 MRI INTERVENTIONS, INC 12
Slide 13: Growth in Case Volume, Revenue
2013 - 2019 Growth in Case Volume, Revenue Case Volume Growth [2013-18] 32.7” CAGR ~ I ™Disposables _™ Biologics and Drug Delivery Capital & Service ™ $11,000 Estimated 2019 Revenue Growth 5 57,359 42% — 56% $913 $1,471 $980 $1,097 $938 2014 2015 2016 2017 2018 2019 (est) 2019 Forecast Revenue Range
Slide 14: Market Potential for Procedures
MARKET POTENTIAL FOR PROCEDURES Included Strategic & Focused Expansion to new geographies either direct or through partners GLOBAL SCALE Below Leverage existing sales channel for other distribution opportunities (i.e. CLS Laser Distributi Expansion & Leverage 50,000+ _Laser Therapy (LITT) for Neuros
Slide 15: Cash Flow From Operations 2015 - 2019
2015 - 2019 “$5,717 Cash Flow From Operations ~ «2» __- $6.2 million © 2019 MRI INTERVENTIONS, INC | 15
Slide 16: Executive Summary
MRIC CAPABILITIES a me Executive Summary — ¢ fal 2) , SR Unique Platform technology 80%+ of forecast revenue from enabling Precision MRI-Guided Therapies to single-use, high-margin restore quality of life for some of the most disposables debilitating disorders 9 _ , « pe : ©) Pipeline of new revenue
MRI Interventions — Investor Presentation (December 2019) on 6ix